Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Ultragenyx Pharma (RARE) Misses Q3 EPS by 28c
November 5, 2019 4:53 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.96), $0.28 worse than the analyst estimate of ($1.68). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $29.12 million.
Strong Crysvita® (burosumab) Launch Continues with Approximately 1,130 Patients on Reimbursed... More